This page contains a Flash digital edition of a book.
SYMPOSIUM


of genomic tools is one of the most promising techniques in the field.


• Accelerate basic and applied re- search and development (R&D) for new antibiotics, other therapeutics, and vaccines. As mentioned, the numbers of newly approved antibiot- ics has sharply decreased, as has the number of private companies invest- ing in the field. In this area, it will be especially important to find innova- tiveways to fund clinically important studies, provide incentives to foster public-private partnerships, and re- duce obstacles to developing novel antimicrobial molecules.


• Improve international collaboration and capacities for antibiotic-resis- tance prevention, surveillance, con- trol, and antibiotic R&D. As a global problem, joining efforts with inter- national agencies and governments is paramount to increase the efficiency of the efforts and improve our chanc- es of success.


CONCLUSION


The immense progress of medical care achieved in the last decades is now threatened by the rise of antibi- otic resistance among hospital- and community-associated pathogens. Al- though there is not a simple solution for this problem, we have witnessed major steps in addressing it. Combating antibiotic resistance


has now become a top public health priority in the United States and around the world and is of particular importance for Texas, which has a robust medical infrastructure dealing with millions of patients with highly complex health problems, with a high proportion of these patients requiring antibiotics during their hospital care. Efforts by academic institutions


to combat antimicrobial resistance in Texas are ongoing and include the creation by the McGovern Medi- cal School at The University of Texas Health Science Center at Houston of a new Center for Antimicrobial Resistance and Microbial Genomics and the establishment of the Anti-


52 TEXAS MEDICINE February 2017


microbial Resistance Cluster by the Gulf Coast Consortia (a collaboration of basic and translational scientists, researchers, clinicians, and students involving seven academic institutions in the Texas Gulf Coast area), among others. A concerted effort from scien- tists, physicians, government admin- istrators, and pharmaceutical com- panies is necessary to win the battle against these emerging super bugs.


Jose M. Munita, MD, is associate pro- fessor of the Clinica Alemana – Univer- sidad del Desarrollo in Santiago, Chile, and adjunct assistant professor of The University of Texas at Houston.


Samuel Shelburne, MD, is associate professor in the departments of Infec- tious Diseases and Genomic Medicine at MD Anderson Cancer Center in Houston.


David E. Greenberg, MD, is an associ- ate professor of infectious diseases and microbiology at The University of Tex- as Southwestern Medical Center.


Cesar A. Arias, MD, is the director of The University of Texas Center for Antimicrobial Resistance and Micro- bial Genomics at the McGovern Medi- cal School at The University of Texas Health Science Center at Houston.


REFERENCES


1. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, ex- tensively drug-resistant and pandrug-resistant bacteria: an international expert pro- posal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.


2. Hersh AL, Newland JG, Beekmann SE, Polgreen PM, GilbertDN.Unmet medical need in infectious diseases. Clin Infect Dis. 2012;54(11):1677–1678.


3.


Centers for Disease Control and Preven- tion. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/ drugresistance/threat-report-2013/index. html. Accessed August 25, 2016.


4. O’Neill J. Antimicrobial Resistance: Tack- ling a Crisis for the Health and Wealth of Nations. Review on antimicrobial resis- tance commissioned by the United King- dom prime minister. December 2014.


5. WorldHealth Organization. Antimicrobial resistance: global report on surveillance 2014. http://www.who.int/drugresistance/ documents/surveillancereport/en/.


6. BoucherHW, TalbotGH, BenjaminDKJr, et al. 10 x ’20 Progress—development of new drugs active against gram-negative bacilli: an update from the Infectious Dis- eases Society of America. Clin Infect Dis. 2013;56(12):1685–1694.


7. Van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant En- terobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75(2):115–120.


8.


Aitken SL, Tarrand JJ, Deshpande LM, 35 al. High rates of nonsusceptibility to ceftazidime-avibactam and identifica- tion of New Delhi metallo-ß-lactamase production in Enterobacteriaceae blood- stream infections at a major cancer center. Clin Infect Dis. 2016;63(7):954–958.


9.


Centers for Disease Control and Preven- tion. Nearly half a million Americans suf- fered fromClostridium difficile infections in a single year. Press release. February 25, 2015. http://www.cdc.gov/media/releas es/2015/p0225-clostridium-difficile.html.


10. Lessa FC, Winston LG, McDonald LC; Emerging Infections Program C. difficile SurveillanceTeam. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369–2370.


11. Talan DA, Krishnadasan A, Gorwitz RJ, et al; EMERGEncy ID Net Study Group. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis. 2011;53(2):144– 149.


12. Rossi F, Diaz L,Wollam A, et al. Transfer- able vancomycin resistance in a communi- ty-associatedMRSAlineage.N Engl J Med. 2014;370(16):1524–1531.


13. Unemo M, Shafer WM. Antimicrobial re- sistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613.


14. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial sus- ceptibility surveillance — The Gonococ- cal Isolate Surveillance Project, 27 Sites, United States, 2014. MMWR Surveill Summ. 2016;65(7):1–19.


15. Miller WR, Murray BE, Rice LB, Arias CA. Vancomycin-resistant Enterococci: therapeutic challenges in the 21st century. Infect Dis Clin North Am. 2016;30(2):415– 439.


16. Perez F, Adachi J, Bonomo RA. Antibiotic- resistant gram-negative bacterial infec- tions in patients with cancer. Clin Infect Dis. 2014;59 Suppl 5:S335–S339.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68